Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. A Formal Prospective Nonrandomized Substudy of the FINESSE Trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)

JACC: Cardiovascular Interventions

Volumn 3, Issue 2, 2010, Pages 203-212

  Montalescot, Gilles ^a   Ellis, Stephen G ^b   de Belder, Mark A ^c   Janssens, Luc ^d   Katz, Olivier ^e   Pluta, Wladyslaw ^f   Ecollan, Patrick ^a   Tendera, Michal ^g   van Boven, Ad J ^h   Widimsky, Petr ⁱ   Andersen, Henning R ^j   Betriu, Amadeo ^k   Armstrong, Paul ^l   Brodie, Bruce R ^m   Herrmann, Howard C ⁿ   Neumann, Franz Josef ^o   Effron, Mark B ^p   Lu, Jiandong ^q   Barnathan, Elliot S ^q   Topol, Eric J ^r  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b LERNER RESEARCH INSTITUTE   (United States)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d IMELDA HOSPITAL   (Belgium)

^e Clinique Saint Joseph   (France)

^f Wojewodzkie Centrum Medyczne   (Poland)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h MEDICAL CENTER LEEUWARDEN   (Netherlands)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k HOSPITAL CLÍNIC   (Spain)

^l UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^m LeBauer Cardiovascular Research Foundation   (United States)

ⁿ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^o UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^p ELI LILLY AND COMPANY   (United States)

^q CENTOCOR INC   (United States)

^r SCRIPPS RESEARCH INSTITUTE   (United States)

more..

Author keywords

heparin; inhibitors; reperfusion

Indexed keywords

ABCIXIMAB; ENOXAPARIN; HEPARIN; RETEPLASE;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 76649119159     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.11.012     Document Type: Article

References (30)

1. Popma J.J., Berger P., Ohman E.M., Harrington R.A., Grines C., and Weitz J.I. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 576S-599S
2. Silber S., Albertsson P., Aviles F.F., et al., The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 26 (2005) 804-847
3. Smith Jr. S.C., Dove J.T., Jacobs A.K., et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 37 (2001) 2215-2238
4. Montalescot G., Bal-dit-Sollier C., Chibedi D., et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 91 (2003) 925-930
5. Montalescot G., Philippe F., Ankri A., et al., French Investigators of the ESSENCE Trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 98 (1998) 294-299
6. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
7. Montalescot G., White H.D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355 (2006) 1006-1017
8. Dumaine R., Borentain M., Bertel O., et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med 167 (2007) 2423-2430
9. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
10. Murphy S.A., Gibson C.M., Morrow D.A., et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28 (2007) 2077-2086
11. Labeque J.N., Jais C., Dubos O., et al. Prehospital administration of enoxaparin before primary angioplasty for ST-elevation acute myocardial infarction. Catheter Cardiovasc Interv 67 (2006) 207-213
12. Montalescot G., Ongen Z., Guindy R., et al. Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. Int J Cardiol 129 (2008) 379-387
13. Ellis S.G., Tendera M., de Belder M.A., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 (2008) 2205-2217
14. Ellis S.G., Armstrong P., Betriu A., et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 147 (2004) E16
15. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 19 (1974) 716-723
16. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
17. Brener S.J., Moliterno D.J., Lincoff A.M., Steinhubl S.R., Wolski K.E., and Topol E.J. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 110 (2004) 994-998
18. Chew D.P., Bhatt D.L., Lincoff A.M., et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 103 (2001) 961-966
19. Sanchez-Pena P., Hulot J.S., Urien S., et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol 60 (2005) 364-373
20. Gibson C.M., Murphy S.A., Montalescot G., et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49 (2007) 2238-2246
21. Zeymer U., Gitt A., Junger C., et al. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction. Thromb Haemost 99 (2008) 150-154
22. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 150 (2005) 116-122
23. Welsh R.C., Gordon P., Westerhout C.M., Buller C.E., O'Neill B., and Armstrong P.W. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Catheter Cardiovasc Interv 70 (2007) 341-348
24. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
25. Montalescot G., Antoniucci D., Kastrati A., et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 28 (2007) 443-449
26. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
27. Collet J.P., Montalescot G., Agnelli G., et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 26 (2005) 2285-2293
28. Danchin N., Collet J., and Marco J. Use of low molecular weight heparin is associated with improved in-hospital survival of ST-elevation myocardial infarction patients who receive reperfusion therapy: Results from the nationwide French FAST-MI registry. Presented at: ACC Scientific Sessions. New Orleans, LA (March 24-27, 2007)
29. Collet J.P., Montalescot G., Vicaut E., et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108 (2003) 391-394
30. Ray K.K., Morrow D.A., Gibson C.M., Murphy S., Antman E.M., and Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 26 (2005) 440-446